Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Richardson, Debra L.
Barve, Minal A.
Strauss, James Fredric
Ulahannan, Susanna Varkey
Moore, Kathleen N.
Hamilton, Erika Paige
Johnson, Melissa Lynne
Papadopoulos, Kyriakos P.
Zarwan, Corrine
Anderson, Charles K.
Buscema, Joseph
Doroshow, Deborah Blythe
Edenfield, William Jeffery
Matulonis, Ursula A.
Burns, Timothy F.
Huebner, Dirk
Jansen, Valerie Malyvanh
Mosher, Rebecca
Jarlenski, Donna
Tolcher, Anthony W.
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Sarah Cannon Res Inst, Stephenson Canc Ctr, Oklahoma City, OK USA
[2] Mary Crowley Canc Res Ctr, Dallas, TX USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[5] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[6] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[7] South Texas Accelerated Res Therapeut LLC, San Antonio, TX USA
[8] Lahey Hosp & Med Ctr, Burlington, MA USA
[9] Willamette Valley Canc Inst, Eugene, OR USA
[10] Arizona Oncol Associates, Tucson, AZ USA
[11] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
[12] Prisma Hlth Upstate Canc Inst, Inst Translat Oncol Res, Greenville, SC USA
[13] Dana Farber Canc Inst, Boston, MA 02115 USA
[14] Univ Pittsburgh, Med Ctr UPMC, Hillman Canc Ctr, Pittsburgh, PA USA
[15] Mersana Therapeut Inc, Cambridge, MA USA
[16] NEXT Oncol, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3549
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I study of oral nintedanib combined with docetaxel in previously treated Japanese patients with advanced non-small cell lung cancer (NSCLC)
    Okamoto, I.
    Miyazaki, M.
    Takeda, M.
    Azuma, K.
    Hayashi, H.
    Seto, T.
    Konishi, K.
    Sarashina, A.
    Kaiser, R.
    Nakagawa, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S830 - S831
  • [32] A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or piatinum-resistant ovarian cancer (OC)
    Weekes, Colin D.
    Lamberts, Laetitia E.
    Borad, Mitesh J.
    Voortman, Johannes
    McWilliams, Robert R.
    Diamond, Jennifer Robinson
    De Vries, Elisabeth
    Verheul, Henk M. W.
    Lieu, Christopher Hanyoung
    Yue, Huibin
    Wang, Yulei
    Scales, Suzie
    Samineni, Divya
    Wood, Katie
    Brunstein, Flavia
    Maslyar, Daniel J.
    Kim, George P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Lisberg, Aaron Elliott
    Sands, Jacob
    Shimizu, Toshio
    Greenberg, Jonathan
    Phillips, Penny
    Guevara, Ferdinand M.
    Noguchi, Yutaka
    Toki, Tadashi
    Spira, Alexander, I
    Yamamoto, Noboru
    Johnson, Melissa L.
    Meric-Bernstam, Funda
    Yoh, Kiyotaka
    Garon, Edward B.
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Phase II study investigating the efficacy and safety of conti nuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC)
    Govindan, R.
    Brahmer, J. R.
    Novello, S.
    Roseli, R.
    Belani, C. P.
    Atkins, J. N.
    Gillenwater, H. H.
    Tye, L.
    Chao, R. C.
    Socinski, M. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 365 - 365
  • [35] Phase I dose-escalating study of 'Tomudex' ('T') and cisplatin (C) in metastatic non-small cell lung cancer (NSCLC): Preliminary results
    Manegold, C
    Buchholz, E
    Kloeppel, R
    Kreisel, C
    Smith, M
    ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
  • [36] Targeting MUC16 with the antibody-drug conjugate (ADC) DMUC5754A in patients with platinum-resistant ovarian cancer: A phase I study of safety and pharmacokinetics.
    Liu, Joyce
    Moore, Kathleen
    Birrer, Michael
    Berlin, Suzanne
    Matulonis, Ursula
    Infante, Jeffrey
    Xi, Jian
    Kahn, Robert
    Wang, Yulei
    Wood, Katie
    Coleman, Daniel
    Maslyar, Daniel
    Humke, Eric
    Burris, Howard
    CANCER RESEARCH, 2013, 73 (08)
  • [37] First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC).
    Gazzah, Anas
    Cousin, Sophie
    Boni, Valentina
    Ricordel, Charles
    Kim, Tae Min
    Kim, Jin-Soo
    Helissey, Carole
    Gardeazabal, Itziar
    Chadjaa, Mustapha
    Allard, Aurore
    Yoruk, Semra
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients
    Madan, Ankit
    Jones, Benjamin S.
    Bordoni, Rodolfo
    Saleh, Mansoor N.
    Jerome, Mary S.
    Miley, Deborah K.
    Jackson, Bradford E.
    Robert, Francisco
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 509 - 515
  • [39] Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients
    Ankit Madan
    Benjamin S. Jones
    Rodolfo Bordoni
    Mansoor N. Saleh
    Mary S. Jerome
    Deborah K. Miley
    Bradford E. Jackson
    Francisco Robert
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 509 - 515
  • [40] Phase II study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases: Final efficacy and safety results
    Novello, S.
    Camps, C.
    Grossi, F.
    Mazieres, J.
    Abrey, L. E.
    Vernejoux, J.
    Thall, A. D.
    Usari, T.
    Chao, R. C.
    Scagliotti, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345